Second Primary Malignancy Following CAR T‑Cell Therapy in Multiple Myeloma Patients: A Meta‑Analysis (ICBMT 2026) - Oct 8, 2026 - Abstract #PP05‑13; "Background/Aim: Chimeric antigen receptor T‑cell (CAR T) therapy, primarily idecabtagene vicleucel and Ciltacabtagene Autoleucel, has transformed the management of relapsed or refractory Multiple Myeloma. Second Primary Malignancy is a clinically and statistically significant adverse effect following treatment with CAR T‑cell therapy in patients with multiple myeloma, with risk increasing with longer follow‑up. Keywords: Second Primary Malignancy, CAR T cell Therapy, Multiple Myeloma, Meta, Mesenchymal"
CAR T-Cell Therapy • Retrospective data • Hematological Malignancies • Multiple Myeloma • Oncology
|
|
Suraj Aryal 1; Anjali Poudel 1
|